#1 Clinical Trials Search in Europe

Teverelix

Teverelix TFA is a gonadotropin-releasing hormone (GnRH) antagonist currently being studied in clinical trials for its potential in treating advanced prostate cancer. This article explores the ongoing research on Teverelix TFA, including its pharmacokinetics, safety, and efficacy in both healthy volunteers and patients with prostate cancer.

Table of Contents

What is Teverelix?

Teverelix, also known by its full chemical name teverelix trifluoroacetate (TFA), is a new medication being studied for the treatment of advanced prostate cancer[2]. It belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) antagonists. These medications work by blocking certain hormones in the body that can fuel the growth of prostate cancer cells[1].

How Does Teverelix Work?

Teverelix works by blocking the action of GnRH in the body. This leads to a decrease in the production of two important hormones: luteinizing hormone (LH) and testosterone. By lowering testosterone levels, teverelix can help slow down or stop the growth of prostate cancer cells, as many prostate cancers rely on testosterone to grow[2].

What Conditions Does Teverelix Treat?

Teverelix is primarily being studied for the treatment of advanced prostate cancer. This refers to prostate cancer that has spread beyond the prostate gland to other parts of the body or has returned after initial treatment[2]. The medication is also being investigated for its potential use in treating prostatic adenoma, which is a non-cancerous enlargement of the prostate gland[2].

How is Teverelix Administered?

Teverelix is given as an injection. There are two main ways it can be administered:

  • Subcutaneous (SC) injection: This is an injection given just under the skin, usually in the abdomen area.
  • Intramuscular (IM) injection: This is an injection given directly into a muscle, often in the buttock area.

The treatment typically involves a loading dose followed by maintenance doses. The loading dose may include both SC and IM injections, while maintenance doses are usually given as SC injections every 4 to 6 weeks[2].

How Effective is Teverelix?

The effectiveness of teverelix is still being studied. Researchers are looking at several measures to determine how well the medication works, including:

  • How quickly and effectively it lowers testosterone levels
  • How long it keeps testosterone levels low
  • Its effects on prostate-specific antigen (PSA) levels, which can be an indicator of prostate cancer activity
  • Its impact on other hormones like luteinizing hormone (LH) and follicle-stimulating hormone (FSH)

Early studies are promising, but more research is needed to fully understand the effectiveness of teverelix compared to other treatments[2].

What Are the Potential Side Effects?

As with any medication, teverelix may cause side effects. Researchers are carefully monitoring for:

  • Injection site reactions: This could include redness, swelling, or discomfort at the injection site.
  • Changes in heart rhythm: Doctors are monitoring for any effects on heart function, particularly changes in the QT interval (a measurement on an ECG).
  • Other side effects: As this is a new medication, researchers are carefully tracking any other adverse events that may occur during treatment[2].

Ongoing Research

Teverelix is currently being studied in clinical trials. These trials are designed to:

  • Determine the best dosing schedule
  • Evaluate how the drug moves through the body (pharmacokinetics)
  • Assess its effects on hormone levels (pharmacodynamics)
  • Measure its effectiveness in treating advanced prostate cancer
  • Monitor for any short-term or long-term side effects

One ongoing study is looking at different dosing regimens, including a 120 mg dose every 6 weeks and a 180 mg dose every 6 weeks[2]. Another study is investigating the drug’s effects in healthy male volunteers to better understand how it works in the body[1].

It’s important to note that as a medication in clinical trials, teverelix is not yet approved for general use. Patients interested in this treatment should speak with their healthcare provider about the possibility of participating in a clinical trial.

Aspect Details
Drug Name Teverelix TFA
Drug Class Gonadotropin-releasing hormone (GnRH) antagonist
Administration Subcutaneous (SC) or Intramuscular (IM) injections
Target Condition Advanced Prostate Cancer
Primary Outcomes Testosterone levels, Pharmacokinetics
Secondary Outcomes LH levels, FSH levels, PSA reduction, Safety profile
Trial Duration Approximately 24 weeks
Dosing Regimen Loading dose followed by maintenance doses at 4-6 week intervals

FAQ

  • What is Teverelix TFA? Teverelix TFA is a gonadotropin-releasing hormone (GnRH) antagonist being studied as a potential treatment for advanced prostate cancer. It works by suppressing hormone levels that can contribute to prostate cancer growth.
  • How is Teverelix TFA administered? Teverelix TFA is administered through subcutaneous (under the skin) or intramuscular (into the muscle) injections. The dosing regimen typically includes a loading dose followed by maintenance doses at regular intervals.
  • What are the main goals of the clinical trials for Teverelix TFA? The main goals are to assess the drug's pharmacokinetics (how the body processes the drug), pharmacodynamics (how the drug affects the body), safety, and efficacy in treating advanced prostate cancer.
  • What are some of the outcomes being measured in these trials? Key outcomes include testosterone and luteinizing hormone levels, prostate-specific antigen (PSA) reduction, time to achieve castrate levels of hormones, and the incidence of treatment-emergent adverse events.
  • How long do the clinical trials for Teverelix TFA typically last? The duration of the trials varies, but the study in prostate cancer patients lasts approximately 24 weeks, with a final assessment 4 weeks after the last dose.

Ongoing Clinical Trials on Teverelix

  • Study on Teverelix for Patients with Advanced Prostate Cancer

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Lithuania

Glossary

  • Gonadotropin-releasing hormone (GnRH) antagonist: A type of medication that blocks the effects of GnRH, a hormone that stimulates the production of sex hormones. In prostate cancer treatment, GnRH antagonists are used to lower testosterone levels.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Subcutaneous (SC) injection: An injection given into the fatty tissue just beneath the skin.
  • Intramuscular (IM) injection: An injection given directly into a muscle.
  • Testosterone: A male sex hormone that can stimulate the growth of prostate cancer cells.
  • Luteinizing Hormone (LH): A hormone that stimulates the production of testosterone in men.
  • Follicle Stimulating Hormone (FSH): A hormone involved in reproductive function and the production of sex hormones.
  • Prostate Specific Antigen (PSA): A protein produced by the prostate gland. Elevated levels may indicate prostate cancer or other prostate conditions.
  • Castrate levels: Very low levels of testosterone, typically achieved through medical or surgical treatment, that are effective in slowing prostate cancer growth.
  • Treatment-emergent Adverse Events (AEs): Side effects or undesirable experiences that occur during treatment with a medication.
  • QTcF interval: A measurement on an electrocardiogram (ECG) that represents the heart's electrical activity. Prolongation of this interval can indicate a risk for certain heart rhythm problems.

References

  1. https://clinicaltrials.gov/study/NCT03781947
  2. https://clinicaltrials.gov/study/NCT04693507